SureTrader
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 1/20/2018 4:47:51 PM - Followers: 218 - Board type: Free - Posts Today: 0



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

Archexin® is a unique anti-sense drug candidate that specifically targets the cancer cell signaling protein Akt-1. Archexin is the only specific inhibitor of Akt-1 in clinical development. The activated form of Akt-1, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance, has been shown to be present or elevated in more than 12 different human cancer cell lines, including pancreatic and renal cell carcinoma. By inhibiting Akt-1, Archexin has shown to inhibit the growth of human renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model. Thus, while Akt-1 is a very specific anti-cancer target, it may have broad therapeutic potential across multiple types of cancer.

RX-3117 is a next generation, orally bioavailable nucleoside analog that is activated (phosphorylated) by the enzyme Uridine Cytidine Kinase 2 (UCK2) and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells. UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues. This unique specificity for cancer cells may lead to an improved efficacy and safety profile in cancer patients. This profile differs from existing nucleoside compounds (such as the widely used chemotherapy gemcitabine), which are activated by the enzyme DCK which is expressed in both cancer cell and in normal healthy tissue leading to significant toxicities at therapeutic doses. RX-3117 has demonstrated broad spectrum anti-tumor activity against 100 different human cancer cell lines (including Non-Small Cell Lung Cancer (NSCLC), breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 17 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.

Supinoxin (RX-5902) is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 (P-p68). P-p68, which is selectively expressed in cancer cells and is absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors, such as melanoma, colon, ovarian and lung.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline

 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

SureTrader
RNN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN News: Current Report Filing (8-k) 01/19/2018 07:31:41 AM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/04/2018 04:57:49 PM
RNN News: Initial Statement of Beneficial Ownership (3) 01/04/2018 04:43:55 PM
RNN News: Current Report Filing (8-k) 01/04/2018 04:24:44 PM
RNN News: Current Report Filing (8-k) 12/21/2017 04:16:49 PM
PostSubject
#3770   RNN hasn't updated their pipeline on their own DorianGray 01/20/18 04:47:51 PM
#3769   Data always looks good but here we are DorianGray 01/20/18 04:45:55 PM
#3768   They presented data from the Phase II Rx-3117 Spideyboy 01/19/18 01:07:57 PM
#3767   just anticipation of news moving this. Anything Tdash 01/19/18 12:47:18 PM
#3766   news leak??News must be good! Are we the gipper 01/19/18 12:19:04 PM
#3765   Let us just hope..... n3m3sis 01/19/18 09:06:10 AM
#3764   Well I was just posting as something is Spideyboy 01/19/18 09:02:11 AM
#3763   Saddle up Belus! n3m3sis 01/19/18 07:59:33 AM
#3762   About Time :) n3m3sis 01/19/18 07:45:50 AM
#3761   Rexahn today to present Phase IIa RX-3117 data Spideyboy 01/19/18 05:17:01 AM
#3760   Working for now, Q1 data will be the tell.GLTA scary larry 01/16/18 04:42:27 PM
#3759   Holding good here from 2.00+. Mr_Popeye 01/16/18 04:39:50 PM
#3758   All good here scary larry 01/16/18 04:29:53 PM
#3757   That's ok, we're on the side of the Mr_Popeye 01/16/18 03:50:51 PM
#3756   Four flat tires out of gas wtf scary larry 01/12/18 03:21:11 PM
#3755   This one rarely holds gains in the long Woulfe 01/12/18 02:54:31 PM
#3754   I think the same thing, Lots of spikes Belus 01/11/18 10:39:00 PM
#3753   Been awhile delayed sheesh scary larry 01/11/18 11:30:10 AM
#3752   Patience..... Mr_Popeye 01/10/18 12:18:53 PM
#3751   It's not starting at all. scary larry 01/10/18 09:54:48 AM
#3750   Looking at a Great Year for Rexahn Phamra, Belus 01/05/18 09:10:19 AM
#3749   Low volume, quiet beginning to 2018. Should make Woulfe 01/02/18 01:30:04 PM
#3748   Aren't we due for THREE catalysts by the JohnnySahn 12/22/17 10:48:59 PM
#3747   Shorts must really be spooked, putting up a the gipper 12/21/17 06:25:22 PM
#3746   Looks Like we are headed North for 2018, :) Belus 12/21/17 08:46:46 AM
#3745   I own a lot of shares in this Belus 12/04/17 10:42:29 PM
#3744   2018 has a lot of potential for RNN. Woulfe 11/28/17 12:05:06 PM
#3743   The silent majority wait quietly DorianGray 11/26/17 12:31:30 PM
#3742   Yo! Where's all the people on Followmylead 11/25/17 10:38:38 AM
#3741   I AGREE!!! n3m3sis 11/09/17 05:44:58 PM
#3740   Good investment now. Big things coming this quarter Followmylead 11/08/17 01:17:31 PM
#3739   Did I miss something or is this another DorianGray 10/31/17 12:56:39 PM
#3738   Get as much as you can at these n3m3sis 10/25/17 03:55:01 PM
#3737   That and I'm hopeful of the institutional buyers DorianGray 10/13/17 02:33:32 PM
#3736   I’d think if the company planned any positive Woulfe 10/13/17 11:46:02 AM
#3735   The only possible saving grace.......... n3m3sis 10/13/17 10:13:52 AM
#3734   It's as if they don't want the share DorianGray 10/13/17 10:10:15 AM
#3733   ...with lots more (150 mil shares originally approved) Theo 10/13/17 10:05:03 AM
#3732   Oh Hell..... n3m3sis 10/13/17 09:32:17 AM
#3731   Seaport Global sets a price target of $13, DorianGray 10/12/17 11:12:37 AM
#3730   Clay Play go away...... n3m3sis 10/10/17 05:30:21 PM
#3729   * * $RNN Video Chart 10-10-17 * * ClayTrader 10/10/17 05:08:32 PM
#3728   38,300 buy @ 3.03.....I'd have to say that the gipper 10/10/17 11:26:51 AM
#3727   Very high probability of ODD approval which can the gipper 10/10/17 11:12:28 AM
#3726   Does this mean the drug will be approved ttubular 10/10/17 10:36:07 AM
#3725   Ripe for a short squeeze, and ODD in the gipper 10/10/17 09:26:27 AM
#3724   Would be nice to see this one bounce Walterwhite666 09/18/17 11:57:31 PM
#3723   Only 23 million float stock should be much otcempire 09/15/17 12:12:01 AM
#3722   RNN Up $0.29 in Pre-Market! n3m3sis 09/11/17 08:40:43 AM
#3721   NEWS!!! "Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from n3m3sis 09/11/17 05:38:27 AM
PostSubject